Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Allergoferon
- Development stage
- Unknown
- Lead developer
- Firn-M
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Topical, Intranasal, Ophthalmic
01
Overview
Allergoferon is a combination therapeutic developed by Firn M, consisting of recombinant human interferon alfa-2b and the antihistamine loratadine. It is indicated for the treatment of perennial and seasonal allergic conjunctivitis as well as allergic rhinitis. The mechanism of action involves interferon alfa-2b binding to the interferon alpha/beta receptor (IFNAR) to exert immunomodulatory and antiviral effects, while loratadine acts as an antagonist at the histamine H1 receptor to mitigate allergic symptoms. This combination is particularly aimed at addressing allergic inflammation while providing protection against respiratory viral infections often associated with allergic conditions. It is approved and marketed in the Russian Federation, typically in a gel formulation for topical application.
- Brand names
- Allergoferon
- Other names
- Аллергоферон
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on Allergoferon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allergoferon.